Asthma maintenance (adults, children 12 or older)
Zolgensma is an adeno-associated virus (AVV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
Hepatitis C infection, chronic
Deep-Vein Thrombosis (treatment), without Symptomatic Pulmonary Embolism
Thrombotic events in Acute Coronary Syndromes, Prevention